CLINICAL_TRIALS
trial_result
· 2020-01-21
Clinical Trial Update: Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma [Phase 2]
Summary
Phase 2 trial investigating dabrafenib and trametinib for BRAF-mutated ameloblastoma has completed with results posted in 2020.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Stanford University | Conditions: Ameloblastoma, BRAF Gene Mutation | Phase 2 | Status: COMPLETED | Results posted: 2020-01-21